(Q40663902)

22 September 2017

E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin (English)

1 reference

22 September 2017

1 reference

1 reference

3

Kelly M McMasters

1 reference

22 September 2017

Yan Bin Dong

1

1 reference

PubMed ID

12637937

22 September 2017

Hai Liang Yang

series ordinal

2

1 reference

22 September 2017

1 March 2003

1 reference

22 September 2017

1 reference

22 September 2017

10

1 reference

22 September 2017

3

1 reference

22 September 2017

168-178

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700565

22 September 2017

0 references

cites work

Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Apoptosis and chemoresistance in transgenic cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

The current status of camptothecin analogues as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

A new component of the transcription factor DRTF1/E2F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

p53 and E2F-1 cooperate to mediate apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

E2F-1-induced p53-independent apoptosis in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

DNA topoisomerases: essential enzymes and lethal targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

Adjuvant therapy of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

7 January 2021

Apoptosis and cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

7 January 2021

Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

7 January 2021

Cell-cycle arrest versus cell death in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

7 January 2021

Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

7 January 2021

E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700565

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700565

1 reference

PubMed ID

12637937

Dimensions Publication ID

22 September 2017

0 references

1 reference

PubMed ID

12637937